Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
accepted:
23
02
2024
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
aheadofprint
Résumé
Combination therapy with docetaxel (DTX) and ramucirumab (RAM) has been used as a second-line treatment for advanced or recurrent lung cancer. However, there is insufficient evidence regarding the safety of angiogenesis inhibitors in older patients. This multicenter retrospective study aimed to investigate the efficacy and safety of second-line treatment regimens in older patients with advanced or recurrent non-small cell lung cancer (NSCLC). We retrospectively analyzed 145 patients aged ≥ 70 years with advanced or recurrent NSCLC treated with second-line chemotherapy after platinum-based therapy between April 1, 2016, and March 31, 2021. Patients were subdivided into the DTX + RAM (n = 38) and single-agent (n = 107) groups. The median time to treatment failure was 6.3 months (95% confidence interval [CI] 3.6-9.6) in the DTX + RAM group and 2.3 months (95% CI 1.7-3.0) in the single-agent group (p < 0.01). The median overall survival was 15.9 months (95% CI 12.3-Not Achieved) in the DTX + RAM group and 9.4 months (95% CI 6.9-15.1) in the single-agent group (p = 0.01). Grade ≥ 3 adverse events frequency was not significantly different between the two groups, except for edema. Patients in the DTX + RAM group who did not discontinue treatment owing to adverse events exhibited the most favorable prognosis. These findings suggest that the DTX + RAM combination is an effective second-line therapy for older patients with advanced or recurrent NSCLC, offering favorable efficacy without treatment discontinuation owing to adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Combination therapy with docetaxel (DTX) and ramucirumab (RAM) has been used as a second-line treatment for advanced or recurrent lung cancer. However, there is insufficient evidence regarding the safety of angiogenesis inhibitors in older patients.
OBJECTIVE
OBJECTIVE
This multicenter retrospective study aimed to investigate the efficacy and safety of second-line treatment regimens in older patients with advanced or recurrent non-small cell lung cancer (NSCLC).
PATIENTS AND METHODS
METHODS
We retrospectively analyzed 145 patients aged ≥ 70 years with advanced or recurrent NSCLC treated with second-line chemotherapy after platinum-based therapy between April 1, 2016, and March 31, 2021. Patients were subdivided into the DTX + RAM (n = 38) and single-agent (n = 107) groups.
RESULTS
RESULTS
The median time to treatment failure was 6.3 months (95% confidence interval [CI] 3.6-9.6) in the DTX + RAM group and 2.3 months (95% CI 1.7-3.0) in the single-agent group (p < 0.01). The median overall survival was 15.9 months (95% CI 12.3-Not Achieved) in the DTX + RAM group and 9.4 months (95% CI 6.9-15.1) in the single-agent group (p = 0.01). Grade ≥ 3 adverse events frequency was not significantly different between the two groups, except for edema. Patients in the DTX + RAM group who did not discontinue treatment owing to adverse events exhibited the most favorable prognosis.
CONCLUSIONS
CONCLUSIONS
These findings suggest that the DTX + RAM combination is an effective second-line therapy for older patients with advanced or recurrent NSCLC, offering favorable efficacy without treatment discontinuation owing to adverse events.
Identifiants
pubmed: 38467958
doi: 10.1007/s11523-024-01045-0
pii: 10.1007/s11523-024-01045-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763 .
doi: 10.3322/caac.21763
pubmed: 36633525
Marosi C, Köller M. Challenge of cancer in the elderly. ESMO Open. 2016;1:e000020. https://doi.org/10.1136/esmoopen-2015-000020 .
doi: 10.1136/esmoopen-2015-000020
pubmed: 27843603
pmcid: 5070391
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92. https://doi.org/10.1056/NEJMoa1801005 .
doi: 10.1056/NEJMoa1801005
pubmed: 29658856
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301. https://doi.org/10.1056/NEJMoa1716948 .
doi: 10.1056/NEJMoa1716948
pubmed: 29863955
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–37. https://doi.org/10.1016/S1470-2045(19)30167-6 .
doi: 10.1016/S1470-2045(19)30167-6
pubmed: 31122901
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211. https://doi.org/10.1016/S1470-2045(20)30641-0 .
doi: 10.1016/S1470-2045(20)30641-0
pubmed: 33476593
Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88. https://doi.org/10.1016/S0140-6736(11)60780-0 .
doi: 10.1016/S0140-6736(11)60780-0
pubmed: 21831418
Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, et al. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (Capital): a randomised, multicentre, open-label, phase 3 trial. Lancet Healthy Longev. 2021;2:e791–800. https://doi.org/10.1016/S2666-7568(21)00255-5 .
doi: 10.1016/S2666-7568(21)00255-5
pubmed: 36098037
Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, et al. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:e196828. https://doi.org/10.1001/jamaoncol.2019.6828 .
doi: 10.1001/jamaoncol.2019.6828
pubmed: 32163097
pmcid: 7068674
Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016;99:186–93. https://doi.org/10.1016/j.lungcan.2016.07.019 .
doi: 10.1016/j.lungcan.2016.07.019
pubmed: 27565938
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–73. https://doi.org/10.1016/S0140-6736(14)60845-X .
doi: 10.1016/S0140-6736(14)60845-X
pubmed: 24933332
Kubo T, Watanabe H, Ninomiya K, Kudo K, Minami D, Murakami E, et al. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Jpn J Clin Oncol. 2020;50:1447–53. https://doi.org/10.1093/jjco/hyaa152 .
doi: 10.1093/jjco/hyaa152
pubmed: 32869100
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244
pubmed: 23208313
Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–5. https://doi.org/10.1200/JCO.2007.13.1144 .
doi: 10.1200/JCO.2007.13.1144
pubmed: 18165641
Wozniak AJ, Kosty MP, Jahanzeb M, Brahmer JR, Spigel DR, Leon L, et al. Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. Clin Oncol (R Coll Radiol). 2015;27:187–96. https://doi.org/10.1016/j.clon.2014.12.002 .
doi: 10.1016/j.clon.2014.12.002
pubmed: 25576353
Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol. 2012;7:203–11. https://doi.org/10.1097/JTO.0b013e3182370e02 .
doi: 10.1097/JTO.0b013e3182370e02
pubmed: 22173662
Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, et al. Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Transl Lung Cancer Res. 2019;8:450–60. https://doi.org/10.21037/tlcr.2019.08.07 .
doi: 10.21037/tlcr.2019.08.07
pubmed: 31555518
pmcid: 6749132
Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, et al. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: a retrospective study. Thorac Cancer. 2022;13:173–81. https://doi.org/10.1111/1759-7714.14236 .
doi: 10.1111/1759-7714.14236
pubmed: 34791812
Katayama Y, Yamada T, Sawada R, Kawachi H, Morimoto K, Watanabe S, et al. Prospective observational study of ramucirumab plus docetaxel after combined chemoimmunotherapy in patients with non-small-cell lung cancer. Oncologist. 2024;2024:oyae001. https://doi.org/10.1093/oncolo/oyae001 .
doi: 10.1093/oncolo/oyae001
Seto Y, Kaneko Y, Mouri T, Fujii H, Tanaka S, Shiotsu S, et al. Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res. 2021;10:193–201. https://doi.org/10.21037/tlcr-20-894 .
doi: 10.21037/tlcr-20-894
pubmed: 33569304
pmcid: 7867752
Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin’s lymphoma. Cancer Control. 2003;10:396–403. https://doi.org/10.1177/107327480301000507 .
doi: 10.1177/107327480301000507
pubmed: 14581895
Wright J, Doan T, McBride R, Jacobson J, Hershman D. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008;98:1197–203. https://doi.org/10.1038/sj.bjc.6604298 .
doi: 10.1038/sj.bjc.6604298
pubmed: 18349836
pmcid: 2359630
Morris M, Platell C, Fritschi L, Iacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer. 2007;96:701–7. https://doi.org/10.1038/sj.bjc.6603627 .
doi: 10.1038/sj.bjc.6603627
pubmed: 17299387
pmcid: 2360063
O’Connor TL, Edge SB, Kossoff EB, Groman A, Wilding GE, Ademuyiwa FO, et al. Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. J Geriatr Oncol. 2012;3:320–8. https://doi.org/10.1016/j.jgo.2012.06.006 .
doi: 10.1016/j.jgo.2012.06.006
Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, et al. Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol. 2021;7:1856–61. https://doi.org/10.1001/jamaoncol.2021.4960 .
doi: 10.1001/jamaoncol.2021.4960
pubmed: 34734989
Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72. https://doi.org/10.1093/annonc/mdr587 .
doi: 10.1093/annonc/mdr587
pubmed: 22250183
Shiotsu S, Yoshimura A, Yamada T, Morimoto K, Tsuchiya M, Yoshioka H, et al. Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: a prospective observational study. Front Oncol. 2022;12:904644. https://doi.org/10.3389/fonc.2022.904644 .
doi: 10.3389/fonc.2022.904644
pubmed: 36158655
pmcid: 9504658
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, et al. Prospective observational study evaluating the prognostic value of the G8 screening tool for extensive-stage small cell lung cancer patients who received programmed death-ligand 1 inhibitor plus platinum-etoposide chemotherapy. Drugs Aging. 2023;40:563–71. https://doi.org/10.1007/s40266-023-01034-4 .
doi: 10.1007/s40266-023-01034-4
pubmed: 37145245